Recent articles

You’re going to hear about a part of your body that, really, goes unnoticed in type 1 diabetes (T1D): blood vessels. But blood vessels are everywhere. From your eye to your lungs to even your pancreas. And they’re really, really important. Do you know that these vessels transport blood cells, nutrients and oxygen to all […]

Beta cell replacement therapies for type 1 diabetes (T1D) have made significant advances in just the past 10 years. We now have insulin-producing beta cells, derived from stem cells, which makes a donor (needed to provide the beta cells) obsolete. We have seen that stem cell-derived precursors can—once implanted in humans—mature into beta cells and […]

ViaCyte, a regenerative medicine company long-supported by Breakthrough T1D, today announced $27 million in financing to continue the development of beta cell therapies for diabetes. This funding ensures that Viacyte’s innovative approaches to replacing the insulin-producing beta cells in people with type 1 diabetes (T1D) will keep progressing. “Beta cell therapies are a key component […]

Mark Poznansky, M.D., Ph.D., wants the seemingly impossible—a person with type 1 diabetes (T1D) has a procedure where beta cells are placed in their body, the doctor stitches it up and the person has functioning insulin-producing beta cells, for life. Of course, we’re not there yet, but, with Dr. Poznansky—and many, many other researchers—Breakthrough T1D […]

In this time of great uncertainty, there is some exciting news out of Europe. Innodia, a partnership between public and private entities working together to fund research aimed at biomarker discovery and the prevention of type 1 diabetes (T1D), received an additional €12 million in funding from the European Commission, Breakthrough T1D and the Helmsley […]

Press releases

Read the latest press releases and statements from Breakthrough T1D.

Get the latest in T1D news updates

Sign up for Insider News to receive breaking news updates from Breakthrough T1D.

  • This field is for validation purposes and should be left unchanged.